Investigations with GMC2021 in experimental models predictive of antimigraine activity and coronary side-effect potential

European Journal of Pharmacology

Volumn 312, Issue 1, 1996, Pages 53-62

  Saxena, Pramod R ^a   De Vries, Peter ^a   Heiligers, Jan P C ^a   MaassenVanDenBrink, Antoinette ^a   Bax, Willem A ^a   Barf, Tjeerd ^b   Wikström, Håkan ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

(Human); (Pig); Antimigraine drug; Arteriovenous anastomosis; Carotid artery; Coronary artery, human; GMC2021; Migraine; Sumatriptan

Indexed keywords

3 [2 (DIMETHYLAMINO)ETHYL] 5 [(TRIFLUOROMETHYL)SULFONYLOXY] 1H INDOLE OXALATE; ANTIMIGRAINE AGENT; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; SEROTONIN ANTAGONIST; SUMATRIPTAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIOVENOUS FISTULA; ARTICLE; CAROTID ARTERY FLOW; CORONARY ARTERY BLOOD FLOW; DRUG ACTIVITY; HEMODYNAMICS; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MIGRAINE; NONHUMAN; PRIORITY JOURNAL; SWINE; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 0030593741     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(96)00443-8     Document Type: Article

References (42)

1. Bax, W.A., G.J. Renzenbrink, D. Van Heuven-Nolsen, E.J.M. Thijssen, E. Bos and P.R. Saxena, 1993, 5-HT receptors mediating contractions of the isolated human coronary artery, Eur. J. Pharmacol. 239, 203.
2. Beattie, D.T., H.E. Connor, W. Feniuk and P.P.A. Humphrey, 1994, The pharmacology of sumatriptan, Rev. Contemp. Pharmacother. 5, 285.
3. 1D receptor agonists sumatriptan and MK-462, Br. J. Pharmacol. 116, 38P.
4. D antagonists, J. Med. Chem. 37, 2253.
5. 2 receptor activation. Eur. J. Pharmacol. 161, 91.
6. 1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan, Br. J. Pharmacol. 102, 323.
7. 1-like receptors, Br. J. Pharmacol. 104, 183.
8. 1D-receptors involved?, Naunyn-Schmiedeberg's Arch. Pharmacol. 345, 509.
9. Den Boer, M.O., L.J. Van Woerkens, J.A.E. Somers, D.J. Duncker, B. Lachmann, P.R. Saxena and P.D. Verdouw, 1993, On the preservation and regulation of vascular tone in arteriovenous anastomoses during anesthesia, J. Appl. Physiol. 75, 782.
10. 1D receptor antagonist, Br. J. Pharmacol. 118, 85.
11. 1A receptor agonist flesinoxan in the cat, J. Cardiovasc. Pharmacol. 14, 770.
12. Feniuk, W., P.P.A. Humphrey and M.J. Perren, 1989, The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs, Br. J. Pharmacol. 96, 83.
13. Ferrari, M.D. and P.R. Saxena, 1993, Clinical and experimental effects of sumatriptan in humans, Trends Pharmacol. Sci. 14, 129.
14. 1Dβ receptor subtype in human and bovine cerebral arteries, Mol. Pharmacol. 44, 242.
15. Heyck, H., 1969, Pathogenesis of migraine, Res. Clin. Stud. Headache 2, 1.
16. Hoyer, D., D.E. Clarke, J.R. Fozard, P.R. Hartig, G.R. Martin, E.J. Mylecharane, P.R. Saxena and P.P.A. Humphrey, 1994, International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin), Pharmacol. Rev. 46, 157.
17. 1-like receptor in dog isolated saphenous vein, Br. J. Pharmacol. 94, 1123.
18. Humphrey, P.P.A., E. Apperley, W. Feniuk and M.J. Perren, 1990, A rational approach to identifying a fundamentally new drug for the treatment of migraine, in: Cardiovascular Pharmacology of 5-Hydroxytryptamine: Prospective Therapeutic Applications, ed. P.R. Saxena, D.I. Wallis, W. Wouters and P. Bevan (Kluwer Academic Publishers, Dordrecht) p. 416.
19. Johnston, B.M. and P.R. Saxena, 1978, The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head, Br. J. Pharmacol. 63, 541.
20. 1Dβ receptors, Circulation 90, 1141.
21. Martin, G.R. and R. Dixon, 1995, Pre-clinical and clinical pharmacology of the novel antimigraine compound 311C90, Poster, American Association for the Study of Headache, Toronto.
22. 1D α receptor sites, Neuropharmacology 34, 235.
23. 1D binding sites, Eur. J. Pharmacol. 163, 133.
24. Saxena, P.R., 1990, Is there still a case for the shunt hypothesis in migraine?, in: Migraine: A Spectrum of Ideas, ed. M. Sandler and G.M. Collins (Oxford University Press, Oxford) p. 191.
25. Saxena, P.R., 1995, Cranial arteriovenous shunting: an in vivo animal model for migraine, in: Experimental Headache Models in Animal and Man, eds. J. Olesen and M.A. Moskowitz (Lippincott-Raven Publishers, Philadelphia) p. 189.
26. Saxena, P.R. and M.D. Ferrari, 1992, From serotonin receptor classification to the antimigraine drug sumatriptan, Cephalalgia 12, 187.
27. Saxena, P.R. and P. Tfelt-Hansen, 1993, Sumatriptan, in: The Headaches, eds. J. Olesen, P. Tfelt-Hansen and K.M.A. Welch (Raven Press Ltd., New York) p. 329.
28. Saxena, P.R. and P.D. Verdouw, 1982, Redistribution by 5-HT on carotid arterial blood at the expense of arteriovenous blood flow, J. Physiol. (London) 332, 501.
29. Saxena, P.R. and C.M. Villalón, 1990, Cardiovascular effects of serotonin agonists and antagonists, J. Cardiovasc. Pharmacol. 15 (Suppl. 7), S17.
30. Saxena, P.R., H.C. Schamhardt, R.P. Forsyth and J. Loeve, 1980, Computer programs for the radioactive microsphere technique. Determination of regional blood flows and other haemodynamic variables in different experimental circumstances, Comp. Progr. Biomed. 12, 63.
31. 1-like receptors, Naunyn-Schmiedeberg's Arch. Pharmacol. 333, 198.
32. 1D receptor agonists in development for the acute treatment of migraine, in: Headache Treatment: Trial Methodology and New Drugs, eds. J. Olesen and P. Tfelt-Hansen (Lippincott-Raven Publishers, Philadelphia) (in press).
33. Schamhardt, H.C., P.D. Verdouw, T.M. Van Der Hoek and P.R. Saxena, 1979, Regional myocardial perfusion and wall thickness and arteriovenous shunting after ergotamine administration to pigs with a fixed coronary stenosis, J. Cardiovasc. Pharmacol. 1, 673.
34. 1D receptors, Naunyn-Schmiedeberg's Arch. Pharmacol. 340, 135.
35. 1D receptor subtype, J. Pharmacol. Exp. Ther. 252, 387.
36. 1D receptor antagonist, Br. J. Pharmacol. 110, 9P.
37. Sonesson, C., M. Boije, K. Svensson, A. Ekman, A. Carlsson, A.G. Romero, I.J. Martin, J.N. Duncan, L.J. King and H. Wikström, 1993, Orally active central dopamine and serotonin receptor ligands: 5-, 6-, 7-, and 8-[[trifluoromethyl)sulfonyl]oxy]-2-(di-n-propylamino)tetralins and the formation of active metabolites in vivo, J. Med. Chem. 36, 3409.
38. Sonesson, C., T. Barf, J. Nilsson, D. Dijkstra, A. Carlsson, K. Svensson, M.W. Smith, I.J. Martin, J.N. Duncan, L.J. King and H. Wikström, 1995, Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogues of 5-, 7-and 8-[[trifluoromethyl)sulfonyl]oxy]-2-aminotetralins, J. Med. Chem. 38, 150.
39. Spierings, E.L.H. and P.R. Saxena, 1980, Antimigraine drugs and cranial arteriovenous shunting in the cat, Neurology 30, 696.
40. The Subcutaneous Sumatriptan International Study Group, 1991, Treatment of migraine with sumatriptan, New Engl. J. Med. 325, 316.
41. Van Es, N.M., T.A. Bruning, J. Camps, P.C. Chang, G.J. Blauw, M.D. Ferrari, P.R. Saxena and P.A. Van Zwieten, 1995, Assessment of peripheral vascular effects of antimigraine drugs in humans, Cephalalgia 15, 288.
42. 1Dβ receptors, Br. J. Pharmacol. 114, 362P.